Phase II trial of Alimta (pemetrexed) and Gemzar (gemcitabine) in metastatic breast cancer patients who have received prior taxane therapy.

Trial Profile

Phase II trial of Alimta (pemetrexed) and Gemzar (gemcitabine) in metastatic breast cancer patients who have received prior taxane therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2009

At a glance

  • Drugs Gemcitabine; Pemetrexed
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 May 2009 Actual patient number (43) added as reported by ClinicalTrials.gov.
    • 07 Feb 2008 Status change from in progress to completed.
    • 16 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top